Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference

Rhea-AI Summary

Fate Therapeutics (NASDAQ: FATE) announced management will participate in the Leerink Partners 2026 Global Healthcare Conference on Monday, March 9, 2026 in Miami, Florida.

Management will join a fireside chat at 9:20 AM ET, host investor meetings, and provide a live webcast with an archived replay available for 90 days.

Key Figures

Conference date: March 9, 2026 Fireside chat time: 9:20 AM ET Webcast replay period: 90 days +5 more

8 metrics

Conference date March 9, 2026 Leerink Partners 2026 Global Healthcare Conference

Fireside chat time 9:20 AM ET Scheduled management fireside chat

Webcast replay period 90 days Archived replay available on company website

Current price $1.50 Pre-news trading level

52-week high $1.9399 Upper end of 52-week trading range

52-week low $0.6611 Lower end of 52-week trading range

Price vs 52-week high -22.68% Distance from 52-week high before this news

Market cap $170,721,388 Equity value prior to conference announcement

Market Reality Check

Price: $1.37 Vol: Volume 1,176,934 is below...

low vol

$1.37 Last Close

Volume Volume 1,176,934 is below the 20-day average of 1,729,739 (relative volume 0.68x). low

Technical Shares at $1.50 are trading above the 200-day MA of $1.17 and about 22.68% below the 52-week high.

Peers on Argus

Peers show mixed moves: CRBP -1.53%, TARA -5.09% vs. EQ +7.87%, FBRX +2.78%, KAL...

Peers show mixed moves: CRBP -1.53%, TARA -5.09% vs. EQ +7.87%, FBRX +2.78%, KALA +2.11%, while FATE is up 1.35%. Combined with no peers in the momentum scanner, this suggests stock-specific trading rather than a coordinated sector move.

Historical Context

5 past events · Latest: Feb 26 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 26	Earnings and update	Positive	+5.4%	Q4 and 2025 results with strong cash and reduced operating expenses.
Feb 03	Inducement awards	Neutral	-0.9%	New-hire stock options and RSUs under Nasdaq inducement rule.
Jan 05	Inducement awards	Neutral	+0.0%	Equity awards to new hires via options and RSUs for recruitment.
Dec 08	Clinical data update	Positive	-0.9%	Updated Phase 1 FT819 data and preclinical advances for FT836/FT839.
Nov 25	Conference presentation	Neutral	-1.9%	Participation in Piper Sandler healthcare conference with fireside chat.

Pattern Detected

Recent news, including earnings and clinical data, has more often seen price moves that align modestly with the news tone, with one notable divergence on positive clinical data.

Recent Company History

Over the last few months, Fate Therapeutics has reported Q4 and full-year 2025 results, highlighted by $205.1 million in cash, projected runway through year-end 2027, and lower operating expenses, which saw a 5.41% positive price reaction. Routine inducement equity awards in January and February 2026 had minimal impact. In December 2025, encouraging Phase 1 FT819 data and preclinical advances for FT836/FT839 coincided with a small negative move, while a November 2025 conference presentation also saw a modest decline. Today’s conference participation fits this pattern of neutral corporate visibility events.

Market Pulse Summary

This announcement signals another investor-relations touchpoint, with Fate hosting a fireside chat a...

Analysis

This announcement signals another investor-relations touchpoint, with Fate hosting a fireside chat at 9:20 AM ET on March 9, 2026 and offering a webcast replay for 90 days. Set against recent earnings that highlighted $205.1 million in cash and runway through 2027, and prior conference participation in late 2025, the news reinforces ongoing outreach rather than a new clinical or financial catalyst. Investors may watch for any incremental commentary on FT819 and the broader iPSC platform.

Key Terms

induced pluripotent stem cell, cellular immunotherapies, webcast

3 terms

induced pluripotent stem cell medical

"a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular"

Cells taken from an adult (such as skin or blood) that scientists ‘reprogram’ so they behave like versatile early-stage cells capable of becoming many different cell types in the body. For investors, these cells matter because they enable development of personalized therapies, safer and faster drug testing, and potential regenerative treatments—like resetting a gadget to factory mode so it can run many different apps—creating new commercial opportunities and affecting biotech valuation and risk.

cellular immunotherapies medical

"iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune"

Cellular immunotherapies are medical treatments that use living immune cells, taken from a patient or donor and then trained, modified, or expanded in a lab so they better recognize and attack disease, such as cancer or infection. For investors, these therapies matter because they can offer dramatic, durable patient responses and premium pricing but also carry high development, manufacturing and regulatory risks—think of them as highly trained sniffer dogs that can be powerful but expensive and complex to deploy.

webcast technical

"A live webcast of the fireside chat can be accessed under “Events"

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

AI-generated analysis. Not financial advice.

SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that management will participate in a fireside chat and host investor meetings at the Leerink Partners 2026 Global Healthcare Conference on Monday, March 9, 2026 in Miami, Florida.

Management will participate in a fireside chat at 9:20 AM ET on Monday, March 9. A live webcast of the fireside chat can be accessed under “Events & Presentations” in the Investors section of the Company’s website at www.fatetherapeutics.com. An archived replay of the webcast will be available for 90 days on the Company’s website following the event.

About Fate Therapeutics, Inc.

Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.

Contact:

Ryan Douglas
Fate Therapeutics, Inc.
IR@fatetherapeutics.com

FAQ

When will Fate Therapeutics (FATE) present at the Leerink Partners 2026 Global Healthcare Conference?

Fate Therapeutics will present on Monday, March 9, 2026 at 9:20 AM ET. According to the company, management will participate in a fireside chat and host investor meetings during the conference in Miami.

How can investors watch the Fate Therapeutics (FATE) fireside chat webcast on March 9, 2026?

Investors can watch the live webcast via the company website under Events & Presentations. According to the company, the webcast is accessible in the Investors section at www.fatetherapeutics.com.

Will the Fate Therapeutics (FATE) webcast from the Leerink 2026 conference be available after the event?

Yes, an archived replay will be available for 90 days following the event. According to the company, the replay will be posted on the company website in the Investors Events & Presentations area.

What topics will Fate Therapeutics (FATE) management cover at the Leerink Partners 2026 conference?

Management will participate in a fireside chat and investor meetings, focusing on company developments and strategy. According to the company, the session is intended to update investors on recent program progress and corporate direction.

Where is the Leerink Partners 2026 Global Healthcare Conference taking place for Fate Therapeutics (FATE)?

The conference is in Miami, Florida on Monday, March 9, 2026. According to the company, Fate Therapeutics management will attend in-person to meet investors and participate in the scheduled fireside chat.